Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:43:00.152Z.
Calculation as of: 2026-10-06T13:43:00.152Z.
Quote observation: 2026-10-06T13:40:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 84870b41b004d4a356f3546a7a12828ec10b1f950fc42869db9e2e4c5d55c05b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$552.97M
EBITDA Yield
N/A
TTM Avg
31.68%
3Y Avg
26.65%
5Y Avg
26.65%
Market Cap
$560.18M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $540.75M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $538.28M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $548.89M | N/A | 1.23% | 1.23% | 1.23% |
| Crescent Biopharma, Inc. (CBIO)vs › | $532.27M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $552.97M | N/A | 31.68% | 26.65% | 26.65% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $560.18M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $518.76M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $562.85M | 55.86% | 22.76% | 17.21% | 17.21% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $512.56M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $570.87M | N/A | 2.38% | 2.38% | 2.38% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
